Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-
A phase 3 trial of Trastuzumab deruxtecan, Bevacizumab in ovarian cancer, run by Daiichi Sankyo, now recruiting.
Overview
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) is a phase 3 interventional study registered as NCT06819007 by Daiichi Sankyo, with 582 participants planned, started 2025-03-19 and due to reach its primary completion in 2028-11-01. Interventions recorded: Trastuzumab Deruxtecan, Bevacizumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Bevacizumab.
- TrialA Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialStudy of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
Shares Bevacizumab, Ovarian cancer.
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan.
- TrialA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Shares Bevacizumab, Ovarian cancer.
- PersonNoboru Yamamoto
Shares Daiichi Sankyo, Trastuzumab deruxtecan.